R

Ryvu Therapeutics

167 employees

Ryvu is a biopharmaceutical company developing small molecule therapies that address clinical limitations of current treatments in oncology.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Pharmaceutical
cancer metabolism
synthetic lethality
HR-MDS
kinase inhibitor
Health Care
drug discovery
oncology
immuno-oncology
Medical
biotech
AML

Date founded

2007

Funding rounds raised

Total raised

$22M

from 3 investors over 3 rounds

R

Ryvu Therapeutics raised $21M on November 30, 2022

Investors: -

R

Ryvu Therapeutics raised $22M on August 17, 2022

Investors: European Investment Bank

R

Ryvu Therapeutics raised $5.6M on June 5, 2020

Investors: NCBR+ Sp. z o.o.

FAQ